ClinicalTrials.gg
CompletedNCT04323605AMA-ALLOUpdated Nov 5, 2026

Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant

An observational study in Hematologic Neoplasms, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University Hospital, Toulouse · Observational

How we know

Updated Nov 5, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Enrollment
31st of 35
50 · median 249
Started
2022
with 9 others
Observational
35 of 142
12 open now
Registered
78th of 142
by date
Lead sponsor
4 of 142
University Hospital, Toulouse

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 31st largest by enrollment of the 35 observational ones that give a count, is one of 10 that started in 2022, is one of 35 observational ones, and was the 78th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

After the initial monitoring period during hospitalization and isolation, patients with recent transplants are regularly monitored in monthly consultations but are still fragile, immunosuppressed and undergoing many treatments. The implementation of an outpatient assistance program for transplant patients should be feasible and allow for the improvement in medical-psycho-social care for the patients during this fragile and risky period, improve the satisfaction and quality of life for these transplant patients and assist in their socio-professional and familial reintegration.

03

Conditions studied

  • Hematologic Neoplasms

Keywords

  • allogeneic hematopoietic stem-cell transplant
  • outpatient assistance
  • "navigation" nurse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who participated in the AMA ALLO program at the IUCT-Oncopole transplant unit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over 18 years of age
  • Having received an hematopoietic stem-cell transplant
  • In full remission
  • Outpatients
  • Having given their for the participation in the outpatient assistance program with a navigation nurse (AMA-ALLO) at the first post-transplant consultation (starting on Day 100 +/- 10 days post-transplant i.e., when the patient passes the initial post-transplant monitoring period in hospitalization (conventional or by day) to the monitoring period in monthly medical consultations) and continuing for 12 months
  • Affiliated with the social security system

Exclusion criteria

Exclusion Criteria:

  • Transplant patients not having given their for inclusion in AMA-ALLO
  • Hospitalized or non-outpatient transplant patients
  • Post-transplant patients in cytological relapse
  • Patients under a legal regime of adult protection (guardianship, curatorship, etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
50 participants (actual)
Patient registry
No

Groups and cohorts

  • outpatient assistance program

    Other: Outpatient assistance program for transplant patients (AMA-ALLO) based on a "navigation" nurse

Interventions

  • OtherOutpatient assistance program for transplant patients (AMA-ALLO) based on a "navigation" nurse

    Integration of a post-transplant "navigation" nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)

06

What researchers measure

Primary outcomes

  1. Rate of patients with all the navigation nurse intervention files received at 100%

    Rate of patients with all the navigation nurse intervention files received at 100%. A file is received at 100% if the 4 following tasks are fully completed: 1. \- patient called by nurse (and response from the patient at the set telephone appointment) 2. \- completion of medical-psycho-social questionnaire (AMA-ALLO phone call form) by nurse with the patient's responses 3. \- information and transmission of questionnaire results by nurse to the transplant physician 4. \- physician/nurse decision for potential intervention (specialized consultation, consultation with the transplant physician, hospitalization, modification of treatments, additional exams to carry out, etc.)

    Time frame: 12 months

Secondary outcomes

  1. Rate of refusal for participation in the study

    Rate of patients who refused participating in the study

    Time frame: 12 months

  2. Rate of ineligibility of the navigation nurse intervention files

    Rate of ineligibility of the navigation nurse intervention files (a single incomplete task out of 4 per intervention file renders the file ineligible)

    Time frame: 12 months

  3. Quality of life for transplant patients

    Quality of life for transplant patients is assessed with the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire version 4. Fo each question, the 5 modality answers are: 0=not all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much

    Time frame: Baseline

  4. Quality of life for transplant patients

    Quality of life for transplant patients is assessed with the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire version 4. Fo each question, the 5 modality answers are: 0=not all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much

    Time frame: 6 months

  5. Quality of life for transplant patients

    Quality of life for transplant patients is assessed with the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire version 4. Fo each question, the 5 modality answers are: 0=not all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much

    Time frame: 12 months

07

Study locations

1 site
  • Toulouse University Hospital
    Toulouse, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2022 to primary completion in Aug 2023, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Jan 2021 → Apr 2022, primary completion Jan 2022 → Aug 2023 and completion Feb 2022 → Aug 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2020
First posted
Mar 26, 2020
StartActual
Apr 28, 2022was Jan 2021
Primary completionActual
Aug 14, 2023was Jan 2022
CompletionActual
Aug 14, 2023was Feb 2022
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 5, 2026
Start date
Jan 2021→Apr 28, 2022 (actual)
Nov 5, 2026
Primary completion
Jan 2022→Aug 14, 2023 (actual)
Nov 5, 2026
Study completion
Feb 2022→Aug 14, 2023 (actual)
Nov 5, 2026
Eligibility
Revised
Nov 5, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionRate of patients with all the navigation nurse intervention files received at 100%: how it is measured was reworded
Nov 5, 2026
Design
Study type Interventional→Observational
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Status unknown→Completed
    Start date Jan 2021→Apr 28, 2022 (now actual)
    Primary completion Jan 2022→Aug 14, 2023 (now actual)
    Study completion Feb 2022→Aug 14, 2023 (now actual)
    Eligibility Revised
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionRate of patients with all the navigation nurse intervention files received at 100%: how it is measured was reworded
    Design Study type Interventional→Observational
    + 4 other changes: index terms, verification date, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04323605
Responsible party
Sponsor
First posted
Mar 26, 2020
Start date
Apr 28, 2022
Primary completion
Aug 14, 2023
Completion
Aug 14, 2023
Last update
Nov 5, 2026

Study contacts

Anne HUYNH, MD
principal investigator · University hospital of Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion